filo Exact Sciences ( NASDAQ: EXAS ) is down ~17% in after-hours trading Wednesday after reporting Q1 2024 results that missed on the bottom line . The company, known for its Cologuard at-home colorectal cancer screening test, also maintained prior revenue guidance of $2.81B-$2.
85B. Consensus is $2.83B.
In the quarter, Exact Sciences saw its net loss widen by ~49% year over year to $110.2B. Net loss per share, basic and diluted, went to -$0.
60 from -$0.42. The company was hurt in Q1 by a ~9% year-over-year increase in total operating expenses to $743.
9M. Exact Sciences ended the quarter (March 31) with cash, cash equivalents, and marketable securities of ~$652.1M compared to ~$777.
6M on Dec. 31, 2023. More on Exact Sciences Exact Sciences: Cancer Battle Continues, Shares Likely To Plateau Exact Sciences Corporation (EXAS) Q4 2023 Earnings Call Transcript Exact Sciences Corporation 2023 Q4 - Results - Earnings Call Presentation Exact Sciences Q1 2024 Earnings Preview Exact Sciences names Aaron Bloomer as CFO.
